Population group: both men and women,
adults (18 - 65 years old)
Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with:
- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of adefovir dipivoxil treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.
- decompensated liver disease in combination with a second agent without cross-resistance to adefovir dipivoxil.
For this indication, competent medicine agencies globally authorize below treatments (click for details):